Gemeinsamer Bundesausschuss (G-BA)

Investment thesis

The G-BA is the central decision-making body of Germany’s self-governing healthcare system, determining the statutory health insurance benefit catalogue and issuing binding regulations on diagnostic and therapeutic interventions. [1]

• It assesses added benefit of new drugs and medical devices to decide if and at what price they are reimbursed by statutory health insurance. [1]
• It mandates early benefit assessments (frühe Nutzenbewertung) for new medicines upon market entry, relying on evidence from manufacturers. [1]
• It defines quality assurance standards and organized disease management programmes, directly shaping clinical pathways for ~73 million insured persons. [1]
• It operates independently of the Federal Ministry of Health but is subject to legal supervision and can have decisions modified by the ministry. [1]

Credibility: The G-BA’s mandate is codified in the Social Code Book V (SGB V), and its binding resolutions are published in the Bundesanzeiger.

Value add

Access to the German statutory health insurance market is contingent on G-BA approval, making it a critical gateway for revenue generation. [1] Fit verdict: Essential for any healthtech or pharma company targeting Germany’s public healthcare system. [1] Founder diligence script:

• What evidence does IQWiG require for my specific therapeutic area?
• How does the G-BA’s current guideline impact my product’s reimbursement pathway?
• What is the typical timeline from dossier submission to final resolution?
• Are there ongoing public consultations that could influence my assessment?

Portfolio focus

The G-BA’s decisions cluster around high-impact therapeutic areas: oncology, rare diseases, cardiovascular conditions, and chronic diseases. [1]

• Recent resolutions include assessments of novel cancer therapies and gene treatments. [1]
• It has expanded coverage for organized disease management programmes, reflecting a focus on preventive care. [1]
• Quality assurance guidelines increasingly emphasize digital health tools and telemedicine. [1]